Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and net

UM > Institute of Chinese Medical Sciences

Residential College	false
Status	已發表Published
	Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and net
	Lei, Qing1 ; Yan, Xin1 ; Zou, Huimin1 ; Jiang, Yixuan1 ; Lai, Yunfeng 2; Ung, Carolina Oi Lam1,3 ; Hu, Hao 1,3
	2022-09
Source Publication	Discover Oncology
ISSN	1868-8497
Indexed By	SCIE
Document Type	Journal article
Collection	Institute of Chinese Medical Sciences
Corresponding Author	Hu, Hao
Affiliation	1.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China 2.School of Public Health and Management, Guangzhou University of Chinese Medicine, Guangzhou, China 3.Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China
First Author Affilication	Institute of Chinese Medical Sciences
Corresponding Author Affilication	Institute of Chinese Medical Sciences; Faculty of Health Sciences
Recommended Citation GB/T 7714	Lei, Qing,Yan, Xin,Zou, Huimin,et al. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and net[J]. Discover Oncology, 2022.
APA	Lei, Qing., Yan, Xin., Zou, Huimin., Jiang, Yixuan., Lai, Yunfeng., Ung, Carolina Oi Lam., & Hu, Hao (2022). Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and net. Discover Oncology.
MLA	Lei, Qing,et al."Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and net".Discover Oncology (2022).

Files in This Item:
There are no files associated with this item.

If you have any objections to this item, please fill out the form below and the administrator will contact you as soon as possible.
Content:
Email：	*
Affiliation No.
Verification Code:	Refresh

Any comments and suggestions are welcomed.
Title:	*
Content:
Email：	*
Verification Code:	Refresh